| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1989.7.3.298 |
| P8608 | Fatcat ID | release_yp35a6qmdbghtcubayycdly3d4 |
| P698 | PubMed publication ID | 2918329 |
| P50 | author | Herbert F. Oettgen | Q108792642 |
| P2093 | author name string | E S Casper | |
| S A Sherwin | |||
| J L Gabrilove | |||
| A A Jakubowski | |||
| M A Templeton | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P304 | page(s) | 298-303 | |
| P577 | publication date | 1989-03-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer | |
| P478 | volume | 7 |
| Q40730935 | A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion |
| Q40738876 | A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor |
| Q33382185 | A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer |
| Q41852980 | Cancer cachexia-when proteasomal inhibition is not enough |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q40875316 | Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV. |
| Q41651824 | Effect of pyridoxine on tumor necrosis factor activitiesin vitro |
| Q42044232 | Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy |
| Q41137657 | Inhibitors of haemopoiesis and their potential clinical relevance. |
| Q43934411 | Intravenous administration of amphotericin B entrapped in liposomes: Induction of high serum levels of TNFα |
| Q37086826 | Invited commentary on David Fedson's article |
| Q35838590 | Pathogenesis of malaria and clinically similar conditions |
| Q36735979 | Prognostic relevance of transforming growth factor alpha (TGF-alpha) and tumor necrosis factor alpha (TNF-alpha) detected in breast cancer tissues by immunohistochemistry |
| Q37803895 | Rationale for immunotherapy of renal cell carcinoma |
| Q67720624 | Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases |
| Q92810873 | Serum amyloid A1 mediates myotube atrophy via Toll-like receptors |
| Q37726527 | Serum cytokines associated with severity and complications of kala-azar. |
| Q33646232 | Sleep electroencephalogram delta-frequency amplitude, night plasma levels of tumor necrosis factor alpha, and human immunodeficiency virus infection |
| Q35640180 | Systemic use of tumor necrosis factor alpha as an anticancer agent |
| Q35196479 | The Therapeutic Potential of Interleukin-1 and Tumor Necrosis Factor on Hematopoietic Stem Cells |
| Q47834672 | The advent of the cytokine storm |
| Q24679558 | The role of TNF-alpha in fever: opposing actions of human and murine TNF-alpha and interactions with IL-beta in the rat |
| Q30857191 | Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical data |
| Q37965274 | Tumor necrosis factor: an update on basic research and clinical applications |
| Q28069390 | Understanding cachexia as a cancer metabolism syndrome |
Search more.